Today’s pharmaceutical and life science businesses deal with many competing pressures, not least the drive to improve ethical business standards
This involves going beyond laws and regulations, establishing new approaches to stakeholder interactions and creating new relationships built on trust and shared values – not easy changes to make in a large corporation.
However, there are a number of current opportunities in the sector - partnering with governments, reaching into developing global markets and discovering sustainable solutions to keep up with the demand for ethical drugs.
Meet our expert
I strongly believe that digital learning can help pharmaceutical and life science organisations prepare and align for the future, by making learning a key focus of their business strategy. Digital technology and especially mobile technology are having a profound disruptive effect on the sector, enabling innovation in everything from the collection of trial data to the ways in which large, international groups of employees are trained and managed.
At LEO, we have the expertise to help everyone, from large pharmaceutical companies that have been around for years – such as Novartis and Roche – to smaller biotechnology companies – like Syngenta – who are operating in niche areas of medicine and are looking to expand. With my team, I work to ensure that these companies are digitally-enabled, innovative and agile enough to keep pace with the rapid rate of change in this fast-moving sector.